價(jià)格 | ¥1138 | ¥1880 | ¥2900 |
包裝 | 50ul | 100ul | 200ul |
最小起訂量 | 50ul |
發(fā)貨地 | 上海 |
更新日期 | 2025-02-14 |
中文名稱:Anti-PRAK antibody-p38調(diào)節(jié)/激活蛋白激酶抗體 | 英文名稱:PRAK |
品牌: 滬震生物 | 產(chǎn)地: 中國(guó)/上海 |
保存條件: -20°C | 純度規(guī)格: > 99% |
產(chǎn)品類別: 抗體 一抗 | |
抗體名: MAP kinase-activated protein kinase 5; PRAK; MAPKAP kinase 5; MAPKAPK5; MAPKAPK5; mitogen-activated protein kinase-activated protein kinase 5; p38-regulated/activated protein kinase. | 靶點(diǎn): 詳見(jiàn)說(shuō)明書(shū) |
宿主: Rabbit | 適應(yīng)物種: 詳見(jiàn)說(shuō)明書(shū) |
克隆性: 詳見(jiàn)說(shuō)明書(shū) | 濃度: 1mg/ml |
應(yīng)用范圍: WB=1:500-2000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=2ug/Test IF=1:100-500 (石蠟切片需做抗原修復(fù)) not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. | 標(biāo)識(shí)物: 詳見(jiàn)說(shuō)明書(shū) |
形態(tài): 液體 | 亞型: IgG1 |
免疫原: 詳見(jiàn)說(shuō)明書(shū) | 貨號(hào): Hz-R4137 |
用途范圍: 科研使用 | 規(guī)格: 50ul/100ul/200ul |
是否進(jìn)口: 否 | 是否單克隆: 詳見(jiàn)說(shuō)明書(shū)p55 |
保質(zhì)期: 12個(gè)月3 | 抗原來(lái)源: 詳見(jiàn)說(shuō)明書(shū) |
標(biāo)記物: 詳見(jiàn)說(shuō)明書(shū) | 產(chǎn)品用途: WB=1:500-2000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=2ug/Test IF=1:100-500 (石蠟切片需做抗原修復(fù)) not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
Host:Rabbit
Target Protein:PRAK
IR:Immunogen Range:89-190/473
Clonality:Polyclonal
Isotype:IgG
Entrez Gene:8550
Swiss Prot:Q8IW41
Source:KLH conjugated synthetic peptide derived from human MAPKAPK5/PRAK:89-190/473
Purification:affinity purified by Protein A
Storage:0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
Background:The serine/threonine kinase PRAK is activated in response to cellular stress and proinflammatory cytokines, through its phosphorylation by MAP kinases including MAPK1/ERK, MAPK14/p38 alpha, and MAPK11/p38 beta. PRAK has been reported to have a putative tumor suppressor function by mediating senescence upon activation by p38 in response to oncogenic ras. It is thought that phosphorylation of p53 by PRAK following activation of p38 MAPK by ras plays an important role in ras induced senescence and tumor suppression.
Size:50ul
Concentration:1mg/ml
Applications:WB(1:500-2000)
IHC-P(1:100-500)
IHC-F(1:100-500)
Flow-Cyt(2ug/Test)
IF(1:100-500)
Cross Reactive Species:Human
Mouse
Rat
Dog
Pig
Cow
Rabbit
本品僅供科研使用。不能用于人和動(dòng)物治療等其它臨床診斷用!
成立日期 | 2014-05-08 (11年) | 注冊(cè)資本 | 100萬(wàn)元整 |
員工人數(shù) | 10-50人 | 年?duì)I業(yè)額 | ¥ 100萬(wàn)以內(nèi) |
主營(yíng)行業(yè) | 生化試劑,細(xì)胞培養(yǎng),蛋白組學(xué),分子生物學(xué),細(xì)胞生物學(xué) | 經(jīng)營(yíng)模式 | 工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP4年
|
上海冠導(dǎo)生物工程有限公司
|
2025-02-14 | |
詢價(jià) |
北京達(dá)科為生物技術(shù)有限公司
|
2025-01-30 | ||
詢價(jià) |
齊一生物科技(上海)有限公司
|
2025-01-30 |